{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:54:06Z","timestamp":1777899246634,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["BC150685"],"award-info":[{"award-number":["BC150685"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.toxrep.2025.102085","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:56:52Z","timestamp":1752613012000},"page":"102085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Acute toxicological evaluation of bone-targeted parathyroid hormone-related peptide (PTHrP) antagonist to inhibit breast cancer metastases to bone"],"prefix":"10.1016","volume":"15","author":[{"given":"Tulasi","family":"Ponnapakkam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muralidharan","family":"Anbalagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Robert E.","family":"Stratford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gensure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxrep.2025.102085_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.toxrep.2025.102085_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","article-title":"Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006","volume":"131","author":"Sathiakumar","year":"2012","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.toxrep.2025.102085_bib3","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1245\/s10434-014-4010-1","article-title":"A promise to our patients with metastatic bone disease","volume":"21","author":"Randall","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.toxrep.2025.102085_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.10.004","article-title":"Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management","volume":"15","author":"D'Oronzo","year":"2019","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.toxrep.2025.102085_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/SPC.0b013e32832f4149","article-title":"New results from the use of bisphosphonates in cancer patients","author":"Coleman","year":"2009","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"10.1016\/j.toxrep.2025.102085_bib6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.0.CO;2-M","article-title":"Parathyroid hormone-related protein and bone metastases","volume":"80","author":"Guise","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.toxrep.2025.102085_bib7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/0008-5472.CAN-10-2993","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.toxrep.2025.102085_bib8","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1038\/s41467-025-59665-7","article-title":"Prolonging parathyroid hormone analog action in vitro and in vivo through peptide lipidation","volume":"16","author":"H\u00f6ppner","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxrep.2025.102085_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/CAD.0000000000001051","article-title":"Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases","volume":"32","author":"Ponnapakkam","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.toxrep.2025.102085_bib10","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1016\/S0021-9258(18)98816-2","article-title":"Mutational analysis of the receptor-activating region of human parathyroid hormone","volume":"266","author":"Gardella","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxrep.2025.102085_bib11","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1210\/endo.140.11.7102","article-title":"Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents","volume":"140","author":"Carter","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.toxrep.2025.102085_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1074\/jbc.275.1.9","article-title":"Photoaffinity cross-linking identifies differences in the interactions of an agonist and an antagonist with the parathyroid hormone\/parathyroid hormone-related protein receptor","volume":"275","author":"Behar","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxrep.2025.102085_bib13","doi-asserted-by":"crossref","first-page":"42692","DOI":"10.1074\/jbc.M106215200","article-title":"Identification of determinants of inverse agonism in a constitutively active parathyroid hormone\/parathyroid hormone-related peptide receptor by photoaffinity cross-linking and mutational analysis","volume":"276","author":"Gensure","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"Apr 1","key":"10.1016\/j.toxrep.2025.102085_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/CAD.0000000000001051","article-title":"Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases","volume":"32","author":"Ponnapakkam","year":"2021","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.toxrep.2025.102085_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/js.2019-OR30-4","article-title":"OR30-4 Parathyroid Hormone-related Peptide Antagonist and Inverse Agonist Reduce Breast Cancer Metastasis to Bone and Bone Loss","volume":"3","author":"Ponnapakkam","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.toxrep.2025.102085_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2125.2004.02194.x","article-title":"The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development","volume":"58","author":"Walker","year":"2004","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.toxrep.2025.102085_bib17","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci."},{"key":"10.1016\/j.toxrep.2025.102085_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jps.23843","article-title":"Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct","volume":"103","author":"Stratford","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxrep.2025.102085_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.toxrep.2025.102085_bib20","first-page":"744","article-title":"Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma","volume":"4","author":"Terpos","year":"2015","journal-title":"Bone Rep."},{"key":"10.1016\/j.toxrep.2025.102085_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2133\/dmpk.DMPK-10-RV-062","article-title":"Mechanisms of drug toxicity and relevance to pharmaceutical development","volume":"26","author":"Guengerich","year":"2011","journal-title":"Drug Metab. Pharmacokinet."}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025002033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025002033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:55:46Z","timestamp":1777629346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750025002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S2214750025002033"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102085","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute toxicological evaluation of bone-targeted parathyroid hormone-related peptide (PTHrP) antagonist to inhibit breast cancer metastases to bone","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102085"}}